Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 159


DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma.

Koomoa DL, Geerts D, Lange I, Koster J, Pegg AE, Feith DJ, Bachmann AS.

Int J Oncol. 2013 Apr;42(4):1219-28. doi: 10.3892/ijo.2013.1835. Epub 2013 Feb 21.


Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma.

Koomoa DL, Yco LP, Borsics T, Wallick CJ, Bachmann AS.

Cancer Res. 2008 Dec 1;68(23):9825-31. doi: 10.1158/0008-5472.CAN-08-1865.


Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells.

Wallick CJ, Gamper I, Thorne M, Feith DJ, Takasaki KY, Wilson SM, Seki JA, Pegg AE, Byus CV, Bachmann AS.

Oncogene. 2005 Aug 25;24(36):5606-18.


AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport.

Samal K, Zhao P, Kendzicky A, Yco LP, McClung H, Gerner E, Burns M, Bachmann AS, Sholler G.

Int J Cancer. 2013 Sep 15;133(6):1323-33. doi: 10.1002/ijc.28139. Epub 2013 May 30.


Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.

Rounbehler RJ, Li W, Hall MA, Yang C, Fallahi M, Cleveland JL.

Cancer Res. 2009 Jan 15;69(2):547-53. doi: 10.1158/0008-5472.CAN-08-2968.


Expression of P27(KIP1) is prognostic and independent of MYCN amplification in human neuroblastoma.

Bergmann E, Wanzel M, Weber A, Shin I, Christiansen H, Eilers M.

Int J Cancer. 2001 May 20;95(3):176-83.


ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.

Hogarty MD, Norris MD, Davis K, Liu X, Evageliou NF, Hayes CS, Pawel B, Guo R, Zhao H, Sekyere E, Keating J, Thomas W, Cheng NC, Murray J, Smith J, Sutton R, Venn N, London WB, Buxton A, Gilmour SK, Marshall GM, Haber M.

Cancer Res. 2008 Dec 1;68(23):9735-45. doi: 10.1158/0008-5472.CAN-07-6866.


Negative cell cycle regulator 14-3-3sigma stabilizes p27 Kip1 by inhibiting the activity of PKB/Akt.

Yang H, Zhang Y, Zhao R, Wen YY, Fournier K, Wu HB, Yang HY, Diaz J, Laronga C, Lee MH.

Oncogene. 2006 Aug 3;25(33):4585-94. Epub 2006 Mar 13.


Suppression of centrosome amplification after DNA damage depends on p27 accumulation.

Sugihara E, Kanai M, Saito S, Nitta T, Toyoshima H, Nakayama K, Nakayama KI, Fukasawa K, Schwab M, Saya H, Miwa M.

Cancer Res. 2006 Apr 15;66(8):4020-9.


Targeting ornithine decarboxylase reverses the LIN28/Let-7 axis and inhibits glycolytic metabolism in neuroblastoma.

Lozier AM, Rich ME, Grawe AP, Peck AS, Zhao P, Chang AT, Bond JP, Sholler GS.

Oncotarget. 2015 Jan 1;6(1):196-206.


The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification.

Geerts D, Koster J, Albert D, Koomoa DL, Feith DJ, Pegg AE, Volckmann R, Caron H, Versteeg R, Bachmann AS.

Int J Cancer. 2010 May 1;126(9):2012-24. doi: 10.1002/ijc.25074.


Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels.

Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N.

Cancer Res. 2008 Jul 1;68(13):5076-85. doi: 10.1158/0008-5472.CAN-08-0634.


PRAF2 stimulates cell proliferation and migration and predicts poor prognosis in neuroblastoma.

Yco LP, Geerts D, Koster J, Bachmann AS.

Int J Oncol. 2013 Apr;42(4):1408-16. doi: 10.3892/ijo.2013.1836. Epub 2013 Feb 21.


Prox1 suppresses the proliferation of neuroblastoma cells via a dual action in p27-Kip1 and Cdc25A.

Foskolou IP, Stellas D, Rozani I, Lavigne MD, Politis PK.

Oncogene. 2013 Feb 21;32(8):947-60. doi: 10.1038/onc.2012.129. Epub 2012 Apr 16.


BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway.

Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD.

J Biol Chem. 2000 Dec 15;275(50):39223-30.


Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation.

Nilsson JA, Keller UB, Baudino TA, Yang C, Norton S, Old JA, Nilsson LM, Neale G, Kramer DL, Porter CW, Cleveland JL.

Cancer Cell. 2005 May;7(5):433-44.


Akt serine threonine kinase regulates platelet-derived growth factor-induced DNA synthesis in glomerular mesangial cells: regulation of c-fos AND p27(kip1) gene expression.

Choudhury GG.

J Biol Chem. 2001 Sep 21;276(38):35636-43. Epub 2001 Jul 26. Erratum in: J Biol Chem 2002 Jan 4;277(1):870.


Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes.

Moros A, Bustany S, Cahu J, Saborit-Villarroya I, Martínez A, Colomer D, Sola B, Roué G.

Clin Cancer Res. 2014 Jan 15;20(2):393-403. doi: 10.1158/1078-0432.CCR-13-1569. Epub 2013 Oct 31.


BCR signals target p27(Kip1) and cyclin D2 via the PI3-K signalling pathway to mediate cell cycle arrest and apoptosis of WEHI 231 B cells.

Banerji L, Glassford J, Lea NC, Thomas NS, Klaus GG, Lam EW.

Oncogene. 2001 Nov 1;20(50):7352-67.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk